Table 3B.
Clinical characteristics of optic neuritis cases associated or not with anti-TNFα in IBD patients [n = 12].
| Evolution to MS during F-U [months] | No [83] | No [7] | No [385] | No [34] | No [Ukn] | No [15] | No [165] | No [13] | No [56] | No [46] | Y [16] | No [52] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ON recurrence | No | No | No | No | No | No | No | No | No | No | Y | Y |
| Visual outcome | Complete recovery | Partial recovery | Complete recovery | Partial recovery | Complete recovery | Partial recovery | Complete recovery | Partial recovery | Partial recovery | Stable | Worsening | Complete recovery |
| Therapy | Pulse MP [3days] | Pulse MP [2 x 3days] / IFN/plasma exchange | No therapy | IFN | Oral prednisone [NS] + Pulse MPa [5days] | Oral prednisone [40 mg] | Oral prednisone [30 mg] | Pulse MPa [3 and 5 days] / IFN | Oral prednisone [80 mg] | No therapy | Pulse MPa [3days] | Pulse MPa [5days] |
| Associated concomitant MS lesions | Y | No | No | Y | No | No | No | Y | No | No | No | No |
| CSF | Abnl | NL | ND | Abnl | ND | ND | ND | Abnl | ND | ND | ND | NL |
| MRI spinal | Abnl | NL | NL | ND | ND | NL | NL | Abnl | ND | ND | NL | NL |
| MRI brain | Abnl | Abnl | NL | Abnl | Abnl | NL | NL | NL | Abnlb | NL | NL | NL |
| MRI orbit | Abnl | Nl | Abnl | ND | Abnl | Nl | Nl | Abnl | ND | NL | NL | NL |
| Cases | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
Abnl, abnormal; CSF, cerebrospinal fluid; F-U, follow-up; IBD, inflammatory bowel disease; IFN, interferon; Mo, months; MP, methylprednisolone; MRI, magnetic resonance imaging; MS, multiple sclerosis; Nl, normal; ND, not done; TNF, tumour necrosis factor; Y, yes.
aOral tapering dose of prednisone.
bNot compatible with demyelinating process.